Edwards Lifesciences (NYSE:EW) Given New $101.00 Price Target at Barclays

Edwards Lifesciences (NYSE:EW - Free Report) had its target price upped by Barclays from $100.00 to $101.00 in a report released on Tuesday morning, Benzinga reports. The brokerage currently has an overweight rating on the medical research company's stock.

EW has been the subject of a number of other research reports. Mizuho raised their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a buy rating in a research note on Thursday, April 11th. Wells Fargo & Company raised their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an overweight rating in a research note on Friday, April 26th. Morgan Stanley raised their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an overweight rating in a research note on Thursday, March 21st. OTR Global raised Edwards Lifesciences from a mixed rating to a positive rating in a research note on Tuesday, March 26th. Finally, Oppenheimer raised their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an outperform rating in a research note on Monday, March 18th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $93.27.

Edwards Lifesciences Trading Up 0.9 %

Shares of NYSE:EW traded up $0.76 during trading on Tuesday, reaching $85.85. 1,836,259 shares of the company traded hands, compared to its average volume of 3,735,495. The firm has a market capitalization of $51.73 billion, a price-to-earnings ratio of 37.00, a P/E/G ratio of 3.59 and a beta of 1.10. Edwards Lifesciences has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The business's fifty day moving average is $90.05 and its 200-day moving average is $79.69.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. As a group, analysts forecast that Edwards Lifesciences will post 2.77 EPS for the current year.

Insider Activity

In related news, Director Heisz Leslie Stone sold 7,056 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $86.45, for a total value of $609,991.20. Following the completion of the sale, the director now directly owns 26,980 shares in the company, valued at approximately $2,332,421. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, CEO Bernard J. Zovighian acquired 580 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, May 6th. The stock was bought at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now owns 3,268 shares of the company's stock, valued at $280,198.32. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Heisz Leslie Stone sold 7,056 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $86.45, for a total value of $609,991.20. Following the completion of the sale, the director now owns 26,980 shares of the company's stock, valued at $2,332,421. The disclosure for this sale can be found here. Insiders sold 237,749 shares of company stock worth $20,920,934 over the last three months. 1.27% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Riverview Trust Co purchased a new position in Edwards Lifesciences in the first quarter worth about $34,000. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $34,000. Rise Advisors LLC boosted its position in Edwards Lifesciences by 125.0% in the first quarter. Rise Advisors LLC now owns 477 shares of the medical research company's stock worth $46,000 after purchasing an additional 265 shares during the last quarter. Finally, Pingora Partners LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth about $38,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.